Sero-epidemiology of Priority Arboviruses in French Guiana
EPI-ARBO
1 other identifier
interventional
2,697
1 country
1
Brief Summary
Dengue is an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories including French Guiana. Rapidly, more than 16,000 suspected local Health authorities had reported cases. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infections in Brazil. The emergence of Zika virus in South America led to a rapid spread throughout South and Central America, reaching French Guiana in December 2015. With the increasing frequency of epidemics related to arbovirus and the resulting health, social, and economic impacts of dengue, the surveillance of arbovirus have become social, political, and public health challenges that require specific and non-available immune status information.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 9, 2017
CompletedFirst Submitted
Initial submission to the registry
June 16, 2017
CompletedFirst Posted
Study publicly available on registry
July 6, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 21, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedSeptember 14, 2020
September 1, 2020
6 months
June 16, 2017
September 11, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Dengue, chikungunya, zika Antibodies detection by multiplex serologic tests
Description of the virological status of individuals by Mutiplex detection of antibodies directed against dengue, chikungunya and zika arboviruses.
2 years
Secondary Outcomes (1)
Seroprevalence by area and age
2 years
Other Outcomes (1)
Dengue infections proportion
2 years
Study Arms (1)
Guiana population
EXPERIMENTALHuman Biological samples from Guiana population : Two serum tubes of blood will be collected
Interventions
Eligibility Criteria
You may qualify if:
- Guiana resident for at least 6 months and present during the entire study period
- Age between 2 and 75 years old
You may not qualify if:
- Subject under guardianship or deprived of liberty by judicial decision
- Subject with any pathology or health problem not compatible with blood sampling
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institut Pasteurlead
Study Sites (1)
Institut Pasteur de la Guyane
Cayenne, 97306, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Claude Flamand
Institut Pasteur de la Guyane
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 16, 2017
First Posted
July 6, 2017
Study Start
June 9, 2017
Primary Completion
November 21, 2017
Study Completion
June 30, 2020
Last Updated
September 14, 2020
Record last verified: 2020-09
Data Sharing
- IPD Sharing
- Will not share